June 17, 2002
Buccal spray or inhaled insulin may be more palatable for most diabetics than repeated injections, and several presentations on June 15 at the American Diabetic Association 62nd Scientific Sessions offer new hope to these patients.
Unlike transdermal or oral capsule forms of insulin, which are still being tested in healthy volunteers, the oral spray and insulin inhaler seem to be effective in early trials with diabetic patients.
"The painful nature of injections is a major problem for type 2 diabetics failing on oral agents and most patients are reluctant to go on injections," write Pankaj Modi and colleagues from Generex Biotechnology Corporation in Toronto, Ontario. "The alternative to this is the RapidMist, a novel diabetes management system based on a unique liquid aerosol formulation of oral insulin (Oralin)."
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!